CRMD Delivers Record Revenue and Raises 2026 Outlook on DefenCath Growth and Pipeline Advancements
Q1 2026 Marks a Turning Point With Revenue Surging Over 225% Year-Over-Year
CorMedix Therapeutics (NASDAQ: CRMD) has kicked off 2026 with a standout quarter, reporting net revenue of $127.4 million—a leap from just $39.1 million in Q1 2025. This rapid growth was powered by the company’s flagship DefenCath product, which alone contributed $97.5 million, and a significant boost from the recently acquired Melinta anti-infective portfolio. Net income climbed to $38.6 million, while adjusted EBITDA reached $70.0 million. The company’s strong financial footing is reflected in its cash and cash equivalents, which totaled $178.1 million as of March 31, 2026.
| Key Metric | Q1 2026 | Q1 2025 | % Change |
|---|---|---|---|
| Net Revenue | $127.43M | $39.08M | +226% |
| Net Income | $38.60M | $20.64M | +87% |
| Adjusted EBITDA | $69.98M | $23.64M | +196% |
| Cash Balance | $178.09M | $144.84M* | +23% |
DefenCath Drives Growth, Even With Temporary Windfalls Factored Out
The lion’s share of the revenue surge stems from DefenCath, which benefited not only from recurring demand but also a one-time $9 million positive adjustment related to sales allowances. Even adjusting for this, DefenCath’s adoption continues to strengthen, especially within outpatient dialysis, aided by the onboarding of a major dialysis organization in 2025. Meanwhile, Melinta’s portfolio added $29.9 million, reflecting solid integration and first-quarter buying trends typical for anti-infectives.
Operating Expenses Reflect Scale, But Profitability Strengthens
Operating expenses grew by 139% year-over-year due to the inclusion of Melinta and expansion in selling, marketing, and clinical research. However, income from operations more than tripled—a signal that margin improvement is keeping pace with the expanding company footprint.
| Expense Type | Q1 2026 | Q1 2025 | % Change |
|---|---|---|---|
| Operating Expenses | $41.46M | $17.36M | +139% |
| R&D | $7.21M | $3.19M | +126% |
| Selling & Marketing | $12.53M | $4.47M | +180% |
| General & Admin | $21.72M | $9.69M | +124% |
Guidance Upside: Full Year Revenue and EBITDA Outlook Raised
Making the most of its momentum, CorMedix upgraded its full-year 2026 revenue forecast to $325–$345 million, from a prior range, and now projects adjusted EBITDA of $115–$135 million. Management’s confidence is bolstered by outperformance across both main business lines and solid progress in pipeline activities.
Pipeline Advancement Sets the Stage for Long-Term Growth
Beyond current sales, the ReSPECT Phase III trial for REZZAYO delivered encouraging topline results, positioning the drug for a supplemental FDA submission later in 2026 and a possible expanded indication launch in 2027. The taurolidine/heparin solution for TPN patients is also on track, with steps underway to accelerate trial enrollment and unlock additional revenue streams post-2027.
Takeaway: Strong Execution and Pipeline Progress Support CRMD’s Growth Ambitions
CorMedix’s first quarter numbers underscore its pivot from a niche player to a diversified, high-growth biopharma. The combination of strong DefenCath adoption, integration of Melinta, and pipeline momentum suggests that current performance improvements are sustainable—not just a flash in the pan. Investors and industry watchers will want to monitor DefenCath’s utilization and the progress of key trials, as the results of ongoing pipeline development could fuel further upside throughout 2026 and beyond.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI